Andreas has developed expertise in all areas of business valuations, including the determining of business enterprise value, valuation intangible assets for corporate and individual clients with particular focus on pharmaceutical, biotechnology and specialty chemicals industries. He also has extensive experience in the telecom, consumer product and manufacturing and financial services industries. Andreas’ clients includes some of the largest pharmaceutical, generic biotechnology and life sciences companies, as well as healthcare systems in the United States, Europe and Asia. Andreas has been involved in numerous multi-billion dollar companies and transactions within his industry focus but also worked with numerous mid-size and start-up companies.
Andreas is a member of the Kroll committee responsible for providing assistance and feedback to the Financial Accounting Standards Board on valuation matters and responded to comments and had discussion with the U.S. Securities and Exchange Commission on valuation issues. Additionally, Andreas has extensive experience in performing valuation under the International Financial Reporting Standards. He has also been a speaker on valuation of intangible assets issues at numerous conferences and has written a number of related papers.
